Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.8 GBX | +2.20% | +2.14% | -3.16% |
Jun. 05 | Berenberg raises Taylor Wimpey to 'buy' | AN |
Jun. 03 | Dr. Martens plc Announces Executive Changes | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Footwear
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.16% | 1.03B | C+ | ||
+61.19% | 27.82B | B+ | ||
+21.79% | 11.14B | - | ||
+28.61% | 10.93B | C+ | ||
+14.57% | 10.8B | C | ||
+57.81% | 8.98B | B- | ||
-5.86% | 7.64B | A- | ||
+19.74% | 3.39B | A- | ||
+69.68% | 2.9B | B- | ||
-9.94% | 2.41B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOCS Stock
- Ratings Dr. Martens plc